Test News – Biocerta Precision Diagnostics, Inc.

Skip to content

Approach
Pipeline
News
About
Contact

Approach
Pipeline
News
About
Contact

Approach
Pipeline
News
About
Contact

Approach
Pipeline
News
About
Contact

Kurt R. Weiss and Douglas P. McCormack: Pittsburgh is an important pl…
archived 17 Jan 2026 20:11:24 UTC

Sign up for updates

Email

Biocerta Precision Diagnostics, Inc.
Bakery Square
6425 Living Pl. Suite 200
Pittsburgh, PA 15206

info@biocertadx.com

Terms of Use
Privacy Policy
Accessibility Statement

Terms of Use
Privacy Policy
Accessibility Statement

COPYRIGHT © 2025 | Biocerta Precision Diagnostics, Inc.

Regulatory Disclaimer

The Biocerta Drug Sensitivity Testing (DST) platform is an investigational device. Federal law restricts this device to investigational use only. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA) and is not available for routine clinical use or commercial distribution. Access is limited to approved clinical research protocols at participating institutions. The safety and effectiveness of this device for cancer treatment selection have not been established.

Test results should not be used as the sole basis for medical decisions. This device has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. For information about clinical trial opportunities or research participation, please contact us.